Royal Bank of Canada Cuts Hookipa Pharma (NASDAQ:HOOK) Price Target to $48.00

Hookipa Pharma (NASDAQ:HOOK) had its price objective decreased by Royal Bank of Canada from $50.00 to $48.00 in a research note issued to investors on Friday morning, Marketbeat.com reports. Royal Bank of Canada currently has an outperform rating on the stock.

Separately, JMP Securities increased their target price on shares of Hookipa Pharma from $23.00 to $24.00 and gave the company a “market outperform” rating in a research report on Friday, August 9th.

Hookipa Pharma Stock Performance

Shares of HOOK opened at $2.80 on Friday. The stock has a 50 day moving average price of $4.09 and a 200 day moving average price of $5.69. Hookipa Pharma has a one year low of $2.76 and a one year high of $11.30. The stock has a market capitalization of $33.75 million, a price-to-earnings ratio of -0.80 and a beta of 0.84.

Institutional Trading of Hookipa Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in shares of Hookipa Pharma in the first quarter valued at about $31,000. Renaissance Technologies LLC raised its stake in Hookipa Pharma by 38.4% during the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after purchasing an additional 83,800 shares during the period. Ikarian Capital LLC acquired a new position in Hookipa Pharma in the 3rd quarter valued at about $228,000. Finally, Acadian Asset Management LLC grew its stake in shares of Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after buying an additional 108,844 shares during the period. 63.88% of the stock is owned by institutional investors and hedge funds.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.